Urologic Health Nabs $11 Million in Seed Funding

Urologic Health Inc. has closed an $11 million seed financing round led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and additional healthcare-focused investors. The funding will support the company’s clinical validation, U.S. Food and Drug Administration 510(k) regulatory pathway, and initial U.S. commercialization efforts.

Bladder dysfunction conditions, including overactive bladder, urinary retention, incontinence, and benign prostatic hyperplasia (BPH), affect hundreds of millions of people worldwide, often requiring ongoing clinical assessment. Current diagnostic tools remain constrained by their high invasiveness and discomfort, which often leads patients to defer or avoid necessary assessments. Urologic Health’s non-invasive niu System is the first and only system designed to close that gap by delivering comprehensive bladder function data without any catheterization, supporting routine, repeatable assessment and longitudinal monitoring of bladder function, according to the company.

“Invasive urodynamics remains one of the most significant barriers in modern urological care,” Urologic Health Co-Founder/CEO Adam Yaacov said. “While treatment options have evolved considerably, the invasive diagnostic process continues to present challenges for patients. Urologic aims to make bladder function assessment easier for clinicians to perform, painless for patients to undergo, and more informative for longitudinal decision-making.”

Urologic Health has completed early feasibility studies demonstrating the niu System can capture clinically meaningful bladder activity non-invasively. The company plans to use the new financing to advance clinical validation, continue product and manufacturing development, and establish its headquarters in Jersey City, N.J., in preparation for initial U.S. market entry.

“Urologic Health was established through our unique venture creation model, which works together with strategic industry partners to identify needs and address them by bringing together entrepreneurs to build high-potential medical device companies,” Edge Medical Managing Partner and Urologic Health Board Chairman Shai Policker stated. “By combining exceptional engineering talent in Israel with Edge’s operational support, we are able to help companies like Urologic Health move faster through clinical validation, regulatory execution, and early market entry in the United States.”

Urologic Health is a medical device company developing non-invasive diagnostic technology for bladder function assessment. Its niu System is designed to capture bladder activity as clinically meaningful diagnostic data without catheterization, supporting more routine and repeatable urodynamic assessment. The company was co-founded by Yaacov and Dr. Noam Omer, who bring expertise in developing medical technologies that advance healthcare through artificial intelligence (AI)-driven insights and data-centric clinical solutions. Urologic Health was founded and incubated at the MEDX Xelerator venture studio (now EdgeLabs) and operates as part of the Edge Medical Ventures portfolio, with operations in the United States and Israel.

The niu System is not yet approved for sale in the United States and is currently limited to investigational use.